• U.S. Burden of Skin and Subcutaneous Diseases Increasing

    Healthday News Conditions, HealthDay News Physician's Briefing June 25, 2020
  • Can dermatology employers require employees to receive the COVID-19 vaccine?

    American Academy of Dermatology AAD, Conditions, Coronavirus, COVID-19 January 28, 2021
  • THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

    American Academy of Dermatology AAD, Atopic Dermatitis, Conditions, Dermatology January 26, 2021
  • Expression of retinoid receptors in hand eczema.

    ClinOwl Atopic Dermatitis, ClinOwl, Conditions, Eczema October 1, 2020
  • S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

    Healthday News Atopic Dermatitis, Conditions, Eczema July 28, 2020
  • Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

    ClinOwl ClinOwl, Conditions, COVID-19, Psoriasis July 26, 2020

DermConnect® is an official licensee of the American Academy of Dermatology.

DermConnect®
Navigation
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
Home Posts Dermatology

Category Archive

  • Dermatology / June 17, 2021

    Review of aluminum, paraben, and sulfate product disclaimers on personal care products.

    View Post
  • Dermatology / November 20, 2020

    Use of Hydrochlorothiazide and Risk of Non-melanoma Skin Cancer in Koreans: A Retrospective Cohort Study Using Administrative Healthcare Data.

    View Post
  • Dermatology / June 11, 2021

    Interpretation of genomic sequence variants in genetic skin diseases: A primer for clinicians.

    View Post
  • Dermatology / June 25, 2021

    Is it possible to repigment iatrogenic and traumatic hypochromic lesions? A case series using the MMP® drug delivery technique with 5-fluorouracil and bleomycin.

    View Post
  • Dermatology / November 25, 2020

    Development of a Core Outcome Set for Cutaneous Squamous Cell Carcinoma Trials: Identification of Core Domains and Outcomes.

    View Post

Multicentric EORTC retrospective study shows efficacy of Brentuximab Vedotin in Μycosis Fungoides and Sezary Syndrome patients with variable CD30 positivity.

In Dermatology
by ClinOwl
June 16, 2021

Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial. Since then few real-life data are available.The aim of this study was to evaluate efficacy …

Scalp dysesthesia and lichen simplex chronicus: diagnostic and therapeutic update with literature review.

In Dermatology
by ClinOwl
June 16, 2021

Scalp dysesthesia and lichen simplex chronicus, conditions that can be associated, are both challenging and frustrating for the patient and the physician. The etiology is not well elucidated and treatment …

Anakinra for recalcitrant pyoderma gangrenosum: a case series.

In Dermatology
by ClinOwl
June 16, 2021

Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that blocks the activity of IL-1α and IL-1β …

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study.

In Dermatology
by ClinOwl
June 14, 2021

Factors that might influence response to systemic treatment for moderate-to-severe psoriasis are varied, and generally, are poorly understood, aside from high body weight, suggesting that other unidentified factors may be …

Development and preliminary validation of the patient-reported Chronic Itch Burden Scale, assessing health-related quality of life in chronic pruritus.

In Dermatology
by ClinOwl
June 14, 2021

Chronic pruritus (CP) significantly affects patients’ health-related quality of life (HRQoL). Very few self-reported HRQoL questionnaires exploring CP were developed according to international guidelines thus limiting their use in pre-authorization …

Oral isotretinoin: 29 years of medical malpractice cases in the United States.

In Dermatology
by ClinOwl
June 14, 2021

Reviews of malpractice claims in the United States show trends of increasing payments with statistically higher payouts for more debilitating and permanent injuries.To examine lawsuits involving notable associated adverse reactions …

The Completeness and Accuracy of DataDerm™: The Database of The American Academy of Dermatology (AAD).

In Dermatology
by ClinOwl
June 13, 2021

The utility of any database or registry depends on the completeness and accuracy of the data it contains. This report documents the validity of data elements within DataDerm, the clinical …

Adverse Pregnancy and Maternal Outcomes in Women with Hidradenitis Suppurativa.

In Dermatology
by ClinOwl
June 13, 2021

Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. However, pregnancy and maternal outcomes for women with HS are unknown.To compare risk of adverse pregnancy and maternal outcomes among women …

Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.

In Dermatology
by ClinOwl
June 13, 2021

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, skin-pain, and sleep disturbances. Currently, dupilumab is the only U.S. FDA approved systemic therapy and biologic medication for …

Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.

In Dermatology
by ClinOwl
June 11, 2021

Delgocitinib 0.5% ointment, a topical JAK inhibitor, has been approved for adult patients with atopic dermatitis (AD) in Japan.To evaluate the efficacy and safety of delgocitinib ointment in pediatric patients …

  • Page 3 of 57
  • ←
  • 1
  • ...
  • 2
  • 3
  • 4
  • ...
  • 57
  • →

TRENDING

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease
  • Lymph Node Dissection Declining in SLN-Positive Melanoma
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

LATEST ARTICLES

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus March 16, 2022
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites March 11, 2022
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease March 11, 2022
  • Lymph Node Dissection Declining in SLN-Positive Melanoma March 9, 2022
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down March 9, 2022

Quick Links

  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

SCHEDULE

August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Mar    

All content indicated on this website as authored by "AAD" is owned by and licensed with the permission of the American Academy of Dermatology (“AAD”) for personal educational use.

The content may not be distributed in whole or in part to any third parties without express written permission from AAD,
nor may viewers of this site translate, edit, modify or otherwise create derivative works from the content.

The licensing of the content by AAD does not constitute or imply any endorsement of any company and/or any of its goods, services or written work product.

 

  • Home
  • Atopic Dermatitis
  • Psoriasis
  • Skin Cancer